This actively managed Exchange Traded Fund (ETF) endeavors to meet its investment goals by typically allocating a minimum of 80% of its total net assets (including any capital secured through borrowing for investment purposes) into the securities of specific companies. To be eligible for inclusion, these companies must either derive at least half of their net revenue from, or commit 50% or more of their assets to, psychedelic compounds, their derivatives, or other financial instruments exhibiting similar economic characteristics. The fund's primary holdings consist of publicly traded life sciences firms focused on psychedelic medical treatments, in addition to other businesses involved in the broader psychedelics sector. It is important to note that this fund maintains a concentrated, non-diversified portfolio.

Definium Therapeutics, Inc.

COMPASS Pathways plc

Atai Beckley Inc.

Relmada Therapeutics, Inc.

NRx Pharmaceuticals, Inc.

Alkermes plc

GH Research PLC

AbbVie Inc.

Bright Minds Biosciences Inc.

Johnson & Johnson

Healthcare

AdvisorShares Psychedelics ETF

PSIL Holdings & Sector Breakdown

PSIL Holdings & Sector Breakdown